Fludarabine
Mast Cell Leukemia
Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Mast Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Stanford University | Phase 2 | BB |
Avapritinib Blueprint Medicines Corporation | Phase 2 | BB |
FILGRASTIM Stanford University | Phase 2 | B |
Brentuximab Vedotin Jason Robert Gotlib | Phase 2 | B |
Solu-Cortef Stanford University | Phase 2 | B |
View all 24 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →